Arca
Skip to content

Hypertrophic cardiomyopathy

Drug research and approvals for hypertrophic cardiomyopathy: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 77 studies of hypertrophic cardiomyopathy are recruiting on ClinicalTrials.gov, Health Canada has authorized 9 drug trials for it since 2013, FDA has 3 approved and 5 open orphan designations naming it, and the EU has 2 authorised medicines for it.

  • Recruiting worldwide: 77
  • Trials authorized in Canada: 9
  • FDA orphan approvals: 3
  • EU medicines: 2

Recruiting Now

Newest start dates first, of 77 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

Newest first; search them all in Canada trials
Oct 7, 2024A phase 2/3 multicenter, randomized, double-blind, placebo-controlled and open-label extension trial to evaluate the efficacy and safety of aficamten in a…AFICAMTEN (CK-3773274)CytokineticsOngoing
Jul 11, 2024A follow-up, open-label, research evaluation of sustained treatment with aficamten (ck-3773274) in hypertrophic cardiomyopathy (hcm)AFICAMTEN (CK-3773274)CytokineticsOngoing
May 22, 2024A phase 3, multi-center, randomized, double-blind trial to evaluate the efficacy and safety of aficamten compared to placebo in adults with symptomatic…AFICAMTEN (CK-3773274)CytokineticsClosed
Jan 26, 2024A randomized, double-blind, placebo-controlled clinical study to evaluate mavacamten adolescents (age 12 years to < 18 years) with symptomatic obstructive…MAVACAMTEN (BMS-986427, MYK-461)Bristol-Myers SquibbOngoing
Aug 23, 2023A phase 3, multi-center, randomized, double-blind trial to evaluate the efficacy and safety of aficamten compared to metoprolol in adults with symptomatic…AFICAMTEN (CK-3773274) / METOPROLOLCytokineticsClosed
Dec 20, 2022A randomized, double-blind, placebo-controlled clinical study to evaluate mavacamten in adults with symptomatic non-obstructive hypertrophic cardiomyopathyMAVACAMTEN (BMS-986427, MYK-461)Bristol-Myers SquibbClosed
Dec 16, 2015Mobilization of endothelial progenitor cells following alcohol septal ablation in hypertrophic obstructive cardiomyopathy: randomized controlled trial of…ACETYLSALICYLIC ACIDOTTAWA HEART INSTITUTE RESEARCH CORPORATIONPending
Aug 8, 2014Phase II randomized, placebo-controlled, double blind clinical trial of valsartan for attenuating disease evolution in early sarcomeric hcm.VALSARTANHOSPITAL FOR SICK CHILDRENClosed
Apr 9, 2014Hcmr - novel predictors of outcome in hypertrophic cardiomyopathyGADOBUTROLDR MATTHIAS FRIEDRICHOngoing

FDA Orphan Designations

Approved first, then open designations, newest first
Sep 30, 2026Camzyostreatment of adults and pediatric patients weighing 30 kg or more with symptomatic obstructive hypertrophic cardiomyopathy (HCM) to improve…MyoKardia, Inc. (a wholly-owned subsidiary of Bristol Myers Squibb)Approved
Dec 19, 2025Myqorzotreatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptomsCytokinetics Inc.Approved
Apr 28, 2022CamzyosTreatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM) to…MyoKardia, Inc. (a wholly-owned subsidiary of Bristol Myers Squibb)Approved
Jul 21, 2026S-Cibenzoline succinatetreatment of obstructive hypertrophic cardiomyopathy (oHCM)Celltrion, Inc.Designated
Jun 18, 2026ninerafaxstattreatment of symptomatic nonobstructive hypertrophic cardiomyopathyImbria Pharmaceuticals, Inc.Designated
May 12, 2021a native AAV9 capsid with a genomic cassette containing a…Treatment of hypertrophic cardiomyopathy (HCM) due to loss-of-function mutations in the MYBPC3 gene encoding cardiac myosin-binding protein…Tenaya TherapeuticsDesignated
Oct 26, 2020DasatinibTreatment of Noonan syndrome-associated hypertrophic cardiomyopathyIGIA Pharmaceuticals, Inc.Designated
Jun 14, 2012perhexiline maleateTreatment of moderate to severe symptomatic hypertrophic cardiomyopathyHeart Metabolics, Limited.Designated

Medicines Authorised in the EU

Newest first
Feb 12, 2026MyqorzoaficamtenCytokinetics (Ireland) LimitedEMA ↗
Jun 26, 2023CamzyosmavacamtenBristol-Myers Squibb Pharma EEIGEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.